Are anti-HIV IgAs good guys or bad guys?

Retrovirology

Volumn 11, Issue 1, 2014, Pages

  Zhou, Mingkui ^a   Ruprecht, Ruth M ^a,b  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^b SOUTHWEST NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

AIDS vaccine development; dIgA2; Dimeric IgA1 (dIgA1); HIV SHIV; IgA; Mucosal transmission; Non human primate models; Passive immunization; RV144 trial; Secretory IgA (SIgA)

Indexed keywords

ERDOSTEINE; FC RECEPTOR; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN A2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; NEUTRALIZING MONOCLONAL ANTIBODY; SECRETORY IMMUNOGLOBULIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN A; IMMUNOLOGIC FACTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ISOLATION; ANTIBODY RESPONSE; ARTICLE; BREAST FEEDING; BREAST MILK; CHIMPANZEE; COMPLEMENT ACTIVATION; CORRELATION ANALYSIS; DEFENSE MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE EXCLUSION; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR; NONHUMAN; PROTEIN PROTEIN INTERACTION; RHESUS MONKEY; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS; TRANSCYTOSIS; VIRION; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION; ANIMAL; ANTIBODY DEPENDENT ENHANCEMENT; IMMUNOLOGY; MEDICAL RESEARCH; METABOLISM; MUCOSAL IMMUNITY; TRENDS;

MACACA MULATTA; PRIMATES; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIBODY-DEPENDENT ENHANCEMENT; BIOMEDICAL RESEARCH; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOLOGIC FACTORS; MACACA MULATTA;

EID: 84924116817     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-014-0109-5     Document Type: Article

References (87)

1. Woof JM, Mestecky J: Mucosal immunoglobulins. Immunol Rev 2005, 206:64-82.
2. Mestecky J, Lamm ME, McGhee JR, Bienenstock J, Mayer L, Strober W: Mucosal Immunology. 3rd edition. Burlington, MA: Elsevier Academic Press; 2005.
3. Mattu TS, Pleass RJ, Willis AC, Kilian M, Wormald MR, Lellouch AC, Rudd PM, Woof JM, Dwek RA: The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcalpha receptor interactions. J Biol Chem 1998, 273:2260-2272.
4. Royle L, Roos A, Harvey DJ, Wormald MR, van Gijlswijk-Janssen D, el RM R, Wilson IA, Daha MR, Dwek RA, Rudd PM: Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J Biol Chem 2003, 278:20140-20153.
5. Tomana M, Niedermeier W, Mestecky J, Skvaril F: The differences in carbohydrate composition between the subclasses of IgA immunoglobulins. Immunochemistry 1976, 13:325-328.
6. Bonner A, Furtado PB, Almogren A, Kerr MA, Perkins SJ: Implications of the near-planar solution structure of human myeloma dimeric IgA1 for mucosal immunity and IgA nephropathy. J Immunol 2008, 180:1008-1018.
7. Furtado PB, Whitty PW, Robertson A, Eaton JT, Almogren A, Kerr MA, Woof JM, Perkins SJ: Solution structure determination of monomeric human IgA2 by X-ray and neutron scattering, analytical ultracentrifugation and constrained modelling: a comparison with monomeric human IgA1. J Mol Biol 2004, 338:921-941.
8. Woof JM, Russell MW: Structure and function relationships in IgA. Mucosal Immunol 2011, 4:590-597.
9. Bonner A, Almogren A, Furtado PB, Kerr MA, Perkins SJ: The nonplanar secretory IgA2 and near planar secretory IgA1 solution structures rationalize their different mucosal immune responses. J Biol Chem 2009, 284:5077-5087.
10. Sumiyama K, Saitou N, Ueda S: Adaptive evolution of the IgA hinge region in primates. Mol Biol Evol 2002, 19:1093-1099.
11. Kawamura S, Omoto K, Ueda S: Evolutionary hypervariability in the hinge region of the immunoglobulin alpha gene. J Mol Biol 1990, 215:201-206.
12. Cole MF, Hale CA: Cleavage of chimpanzee secretory immunoglobulin A by Haemophilus influenzae IgA1 protease. Microb Pathog 1991, 11:39-46.
13. Burnett RC, Hanly WC, Zhai SK, Knight KL: The IgA heavy-chain gene family in rabbit: cloning and sequence analysis of 13 C alpha genes. EMBO J 1989, 8:4041-4047.
14. Brown WR, Butler JE: Characterization of a C alpha gene of swine. Mol Immunol 1994, 31:633-642.
15. Patel M, Selinger D, Mark GE, Hickey GJ, Hollis GF: Sequence of the dog immunoglobulin alpha and epsilon constant region genes. Immunogenetics 1995, 41:282-286.
16. Knight KL, Becker RS: Isolation of genes encoding bovine IgM, IgG, IgA and IgE chains. Vet Immunol Immunopathol 1987, 17:17-24.
17. Schneiderman RD, Hanly WC, Knight KL: Expression of 12 rabbit IgA C alpha genes as chimeric rabbit-mouse IgA antibodies. Proc Natl Acad Sci U S A 1989, 86:7561-7565.
18. Crago SS, Kutteh WH, Moro I, Allansmith MR, Radl J, Haaijman JJ, Mestecky J: Distribution of IgA1-, IgA2-, and J chain-containing cells in human tissues. J Immunol 1984, 132:16-18.
19. Tregoat V, Montagne P, Bene MC, Faure G: Increases of IgA milk concentrations correlate with IgA2 increment. J Clin Lab Anal 2001, 15:55-58.
20. Kilian M, Mestecky J, Kulhavy R, Tomana M, Butler WT: IgA1 proteases from Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis , and Streptococcus sanguis: comparative immunochemical studies. J Immunol 1980, 124:2596-2600.
21. Male CJ: Immunoglobulin A1 protease production by Haemophilus influenzae and Streptococcus pneumoniae . Infect Immun 1979, 26:254-261.
22. Senior BW, Dunlop JI, Batten MR, Kilian M, Woof JM: Cleavage of a recombinant human immunoglobulin A2 (IgA2)-IgA1 hybrid antibody by certain bacterial IgA1 proteases. Infect Immun 2000, 68:463-469.
23. Kaetzel CS: The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol Rev 2005, 206:83-99.
24. Kaetzel CS, Robinson JK, Chintalacharuvu KR, Vaerman JP, Lamm ME: The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. Proc Natl Acad Sci U S A 1991, 88:8796-8800.
25. Braathen R, Hohman VS, Brandtzaeg P, Johansen FE: Secretory antibody formation: conserved binding interactions between J chain and polymeric Ig receptor from humans and amphibians. J Immunol 2007, 178:1589-1597.
26. Fahrbach KM, Malykhina O, Stieh DJ, Hope TJ: Differential binding of IgG and IgA to mucus of the female reproductive tract. PLoS One 2013, 8:e76176.
27. Strober W, Krakauer R, Klaeveman HL, Reynolds HY, Nelson DL: Secretory component deficiency. A disorder of the IgA immune system. N Engl J Med 1976, 294:351-356.
28. Merrill WW, Goodenberger D, Strober W, Matthay RA, Naegel GP, Reynolds HY: Free secretory component and other proteins in human lung lavage. Am Rev Respir Dis 1980, 122:156-161.
29. Johansen FE, Kaetzel CS: Regulation of the polymeric immunoglobulin receptor and IgA transport: new advances in environmental factors that stimulate pIgR expression and its role in mucosal immunity. Mucosal Immunol 2011, 4:598-602.
30. Vaerman JP, Heremans JF, Van Kerckhoven G: Identification of IgA in several mammalian species. J Immunol 1969, 103:1421-1423.
31. Kawamura S, Saitou N, Ueda S: Concerted evolution of the primate immunoglobulin alpha-gene through gene conversion. J Biol Chem 1992, 267:7359-7367.
32. Tucker PW, Slightom JL, Blattner FR: Mouse IgA heavy chain gene sequence: implications for evolution of immunoglobulin hinge axons. Proc Natl Acad Sci U S A 1981, 78:7684-7688.
33. Aucouturier P, Duarte F, Mihaesco E, Pineau N, Preud'homme JL: Jacalin, the human IgA1 and IgD precipitating lectin, also binds IgA2 of both allotypes. J Immunol Methods 1988, 113:185-191.
34. Gregory RL, Rundegren J, Arnold RR: Separation of human IgA1 and IgA2 using jacalin-agarose chromatography. J Immunol Methods 1987, 99:101-106.
35. Johnsson E, Areschoug T, Mestecky J, Lindahl G: An IgA-binding peptide derived from a streptococcal surface protein. J Biol Chem 1999, 274:14521-14524.
36. Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser JD: The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria. J Immunol 2005, 174:2926-2933.
37. Loomes LM, Stewart WW, Mazengera RL, Senior BW, Kerr MA: Purification and characterization of human immunoglobulin IgA1 and IgA2 isotypes from serum. J Immunol Methods 1991, 141:209-218.
38. Sandin C, Linse S, Areschoug T, Woof JM, Reinholdt J, Lindahl G: Isolation and detection of human IgA using a streptococcal IgA-binding peptide. J Immunol 2002, 169:1357-1364.
39. Ramsland PA, Willoughby N, Trist HM, Farrugia W, Hogarth PM, Fraser JD, Wines BD: Structural basis for evasion of IgA immunity by Staphylococcus aureus revealed in the complex of SSL7 with Fc of human IgA1. Proc Natl Acad Sci U S A 2007, 104:15051-15056.
40. Pabst O: New concepts in the generation and functions of IgA. Nat Rev Immunol 2012, 12:821-832.
41. Macpherson AJ, Gatto D, Sainsbury E, Harriman GR, Hengartner H, Zinkernagel RM: A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 2000, 288:2222-2226.
42. Neutra MR, Kozlowski PA: Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
43. Rogers KA, Jayashankar L, Scinicariello F, Attanasio R: Nonhuman primate IgA: genetic heterogeneity and interactions with CD89. J Immunol 2008, 180:4816-4824.
44. Wende H, Colonna M, Ziegler A, Volz A: Organization of the leukocyte receptor cluster (LRC) on human chromosome 19q13.4. Mamm Genome 1999, 10:154-160.
45. van Egmond M, van Garderen E, van Spriel AB, Damen CA, van Amersfoort ES, van Zandbergen G, van Hattum J, Kuiper J, van de Winkel JG: FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med 2000, 6:680-685.
46. Woof JM, Burton DR: Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 2004, 4:89-99.
47. Black KP, Cummins JE Jr, Jackson S: Serum and secretory IgA from HIV-infected individuals mediate antibody-dependent cellular cytotoxicity. Clin Immunol Immunopathol 1996, 81:182-190.
48. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR: Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001, 167:2861-2868.
49. Shibuya A, Honda S: Molecular and functional characteristics of the Fcalpha/muR, a novel Fc receptor for IgM and IgA. Springer Semin Immunopathol 2006, 28:377-382.
50. McDonald KJ, Cameron AJ, Allen JM, Jardine AG: Expression of Fc alpha/mu receptor by human mesangial cells: a candidate receptor for immune complex deposition in IgA nephropathy. Biochem Biophys Res Commun 2002, 290:438-442.
51. Wang R, Fu Y, Zhao Q, Pan L, Zhang W: Human Fcalpha/muR and pIgR distribute differently in intestinal tissues. Biochem Biophys Res Commun 2009, 381:148-152.
52. Kikuno K, Kang DW, Tahara K, Torii I, Kubagawa HM, Ho KJ, Baudino L, Nishizaki N, Shibuya A, Kubagawa H: Unusual biochemical features and follicular dendritic cell expression of human Fcalpha/mu receptor. Eur J Immunol 2007, 37:3540-3550.
53. Watkins JD, Sholukh AM, Mukhtar MM, Siddappa NB, Lakhashe SK, Kim M, Reinherz EL, Gupta S, Forthal DN, Sattentau QJ, Villinger F, Corti D, Ruprecht RM, CAVD Project Group: Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 2013, 27:F13-F20.
54. Burnett PR, VanCott TC, Polonis VR, Redfield RR, Birx DL: Serum IgA-mediated neutralization of HIV type 1. J Immunol 1994, 152:4642-4648.
55. Devito C, Broliden K, Kaul R, Svensson L, Johansen K, Kiama P, Kimani J, Lopalco L, Piconi S, Bwayo JJ, Plummer F, Clerici M, Hinkula J: Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000, 165:5170-5176.
56. Benjelloun F, Dawood R, Urcuqui-Inchima S, Rochereau N, Chanut B, Verrier B, Lucht F, Genin C, Paul S: Secretory IgA specific for MPER can protect from HIV-1 infection in vitro. AIDS 2013, 27:1992-1995.
57. Nishiyama Y, Karle S, Planque S, Taguchi H, Paul S: Antibodies to the superantigenic site of HIV-1 gp120: hydrolytic and binding activities of the light chain subunit. Mol Immunol 2007, 44:2707-2718.
58. Planque S, Salas M, Mitsuda Y, Sienczyk M, Escobar MA, Mooney JP, Morris MK, Nishiyama Y, Ghosh D, Kumar A, Gao F, Hanson CV, Paul S: Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. AIDS 2010, 24:875-884.
59. Planque SA, Mitsuda Y, Nishiyama Y, Karle S, Boivin S, Salas M, Morris MK, Hara M, Liao G, Massey RJ, Hanson CV, Paul S: Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine. J Immunol 2012, 189:5367-5381.
60. Burns JW, Siadat-Pajouh M, Krishnaney AA, Greenberg HB: Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996, 272:104-107.
61. Robinson JK, Blanchard TG, Levine AD, Emancipator SN, Lamm ME: A mucosal IgA-mediated excretory immune system in vivo. J Immunol 2001, 166:3688-3692.
62. Wright A, Lamm ME, Huang YT: Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A. J Virol 2008, 82:11526-11535.
63. Devito C, Hinkula J, Kaul R, Kimani J, Kiama P, Lopalco L, Barass C, Piconi S, Trabattoni D, Bwayo JJ, Plummer F, Clerici M, Broliden K: Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J Acquir Immune Defic Syndr 2002, 30:413-420.
64. Broliden K, Hinkula J, Devito C, Kiama P, Kimani J, Trabbatoni D, Bwayo JJ, Clerici M, Plummer F, Kaul R: Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett 2001, 79:29-36.
65. Kaul R, Plummer F, Clerici M, Bomsel M, Lopalco L, Broliden K: Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS 2001, 15:431-432.
66. Mazzoli S, Lopalco L, Salvi A, Trabattoni D, Lo Caputo S, Semplici F, Biasin M, Bl C, Cosma A, Pastori C, Meacci F, Mazzotta F, Villa ML, Siccardi AG, Clerici M: Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis 1999, 180:871-875.
67. Kaul R, Trabattoni D, Bwayo JJ, Arienti D, Zagliani A, Mwangi FM, Kariuki C, Ngugi EN, MacDonald KS, Ball TB, Clerici M, Plummer FA: HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 1999, 13:23-29.
68. Pastori C, Barassi C, Piconi S, Longhi R, Villa ML, Siccardi AG, Clerici M, Lopalco L: HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket. J Biol Regul Homeost Agents 2000, 14:15-21.
69. Clerici M, Barassi C, Devito C, Pastori C, Piconi S, Trabattoni D, Longhi R, Hinkula J, Broliden K, Lopalco L: Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS 2002, 16:1731-1741.
70. Buchacz K, Parekh BS, Padian NS, van der Straten A, Phillips S, Jonte J, Holmberg SD: HIV-specific IgG in cervicovaginal secretions of exposed HIV-uninfected female sexual partners of HIV-infected men. AIDS Res Hum Retroviruses 2001, 17:1689-1693.
71. Dorrell L, Hessell AJ, Wang M, Whittle H, Sabally S, Rowland-Jones S, Burton DR, Parren PW: Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS 2000, 14:1117-1122.
72. Ghys PD, Belec L, Diallo MO, Ettiegne-Traore V, Becquart P, Maurice C, Nkengasong JN, Coulibaly IM, Greenberg AE, Laga M, Wiktor SZ: Cervicovaginal anti-HIV antibodies in HIV-seronegative female sex workers in Abidjan, Cote d'Ivoire. AIDS 2000, 14:2603-2608.
73. Skurnick JH, Palumbo P, DeVico A, Shacklett BL, Valentine FT, Merges M, Kamin-Lewis R, Mestecky J, Denny T, Lewis GK, Lloyd J, Praschunus R, Baker A, Nixon DF, Stranford S, Gallo R, Vermund SH, Louria DB: Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J Infect Dis 2002, 185:428-438.
74. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, Mouz N, Amacker M, Chalifour A, Diomede L, Devillier G, Cong Z, Wei Q, Gao H, Qin C, Yang GB, Zurbriggen R, Lopalco L, Fleury S: Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34:269-280.
75. Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, Moog C, Reynes JM, Lopalco L, Bomsel M: HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009, 2:412-426.
76. World Health Organization: Guidelines on HIV and infant feeding 2010. Principles and recommendations for infant feeding in the context of HIV and a summary of evidence. In Geneva: WHO Press, World Health Organization; 2010.
77. Doherty T, Chopra M, Jackson D, Goga A, Colvin M, Persson LA: Effectiveness of the WHO/UNICEF guidelines on infant feeding for HIV-positive women: results from a prospective cohort study in South Africa. AIDS 2007, 21:1791-1797.
78. Kuhn L, Trabattoni D, Kankasa C, Sinkala M, Lissoni F, Ghosh M, Aldrovandi G, Thea D, Clerici M: HIV-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants. J Pediatr 2006, 149:611-616.
79. Kaul R: Maternal milk IgA and mother-to-child transmission of human immunodeficiency virus: not a silver spoon. J Pediatr 2006, 149:591-593.
80. Kozlowski PA, Black KP, Shen L, Jackson S: High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons. Masking by IgG. J Immunol 1995, 154:6163-6173.
81. Janoff EN, Wahl SM, Thomas K, Smith PD: Modulation of human immunodeficiency virus type 1 infection of human monocytes by IgA. J Infect Dis 1995, 172:855-858.
82. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH, MOPH-TAVEG Investigators: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
83. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, et al: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.
84. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao HX, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, Poling B, Nicholson CO, Zhang R, Lu X, Parks R, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Gilbert PB, Kim JH, Michael NL, Montefiori DC, Haynes BF: Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 2013, 110:9019-9024.
85. Blutt SE, Miller AD, Salmon SL, Metzger DW, Conner ME: IgA is important for clearance and critical for protection from rotavirus infection. Mucosal Immunol 2012, 5:712-719.
86. Nishio O, Sakae K, Ishihara Y, Isomura S, Inouye S: Adenovirus infection and specific secretory IgA responses in the intestine of infants. Microbiol Immunol 1992, 36:623-631.
87. Buisman A-M, Abbink F, Schepp RM, Sonsma JAJ, Herremans T, Kimman TG: Preexisting poliovirus-specific IgA in the circulation correlates with protection against virus excretion in the elderly. J Infect Dis 2008, 197:698-706.